Endonovo Therapeutics

Endonovo Therapeutics (OTCQB: ENDV) is a commercial-stage developer of non-invasive medical devices, aiming to deliver its proprietary Electroceutical™ therapy for the treatment of inflammation, cardiovascular diseases, and central nervous system disorders.Endonovo's Electroceutical™ therapy is FDA-approved for palliative treatment of pain and postoperative edema (swelling) and bears the CE mark for promoting wound healing and providing palliative treatment for pain and postoperative edema. Endonovo’s Electroceutical™ therapy has CMS national coverage for the treatment of chronic wounds. The company’s current clinical-stage Electroceutical™ therapy portfolio targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussion, post-concussion syndrome, traumatic brain injury (TBI), and multiple sclerosis.